Jacobs Levy Equity Management Inc. Invests $572,000 in Cryoport, Inc. (NASDAQ:CYRX)

Jacobs Levy Equity Management Inc. bought a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 73,537 shares of the company’s stock, valued at approximately $572,000. Jacobs Levy Equity Management Inc. owned about 0.15% of Cryoport as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Avanza Fonder AB acquired a new position in Cryoport in the fourth quarter worth about $64,000. Quarry LP acquired a new position in Cryoport in the fourth quarter worth about $69,000. Nebula Research & Development LLC grew its stake in Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after purchasing an additional 2,207 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Cryoport by 135.5% in the fourth quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock worth $100,000 after purchasing an additional 7,407 shares in the last quarter. Finally, Olympiad Research LP acquired a new position in Cryoport in the fourth quarter worth about $103,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Stock Performance

Shares of CYRX stock opened at $6.68 on Friday. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The business has a 50 day moving average of $5.95 and a two-hundred day moving average of $6.86. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $12.58. The company has a market cap of $334.92 million, a P/E ratio of -1.98 and a beta of 1.92.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The company had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. As a group, analysts anticipate that Cryoport, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Roth Mkm reiterated a “buy” rating and issued a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley decreased their target price on Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Finally, UBS Group lifted their target price on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 19,830 shares of company stock worth $118,353. Company insiders own 10.00% of the company’s stock.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.